{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:28:55Z","timestamp":1791246535807,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.phrs.2019.104587","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T12:14:25Z","timestamp":1575375265000},"page":"104587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"special_numbering":"C","title":["\u03b2-blockers: Their new life from hypertension to cancer and migraine"],"prefix":"10.1016","volume":"151","author":[{"given":"Carlo","family":"Fumagalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Maurizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fornasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2019.104587_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1254\/jphs.CRJ06001X","article-title":"Cardiac adrenoceptors: physiological and pathophysiological relevance","volume":"100","author":"Brodde","year":"2006","journal-title":"J Pharmacol Sci [Internet]"},{"key":"10.1016\/j.phrs.2019.104587_bib0010","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/B978-0-12-381296-4.00003-8","article-title":"Measurement of inverse agonism in \u03b2-adrenoceptors","author":"Taira","year":"2010"},{"issue":"8","key":"10.1016\/j.phrs.2019.104587_bib0015","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/sj.bjp.0703992","article-title":"Characterization of \u03b21-selectivity, adrenoceptor-Gs-protein interaction and inverse agonism of nebivolol in human myocardium","volume":"132","author":"Maack","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104587_bib0020","first-page":"227","article-title":"Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling","volume":"Vol. 32","author":"Baker","year":"2011"},{"issue":"7","key":"10.1016\/j.phrs.2019.104587_bib0025","doi-asserted-by":"crossref","first-page":"R324","DOI":"10.1016\/j.cub.2018.02.027","article-title":"GPCR signaling: the interplay of g\u03b1i and \u03b2-arrestin","volume":"28","author":"Dwivedi","year":"2018","journal-title":"Curr. Biol."},{"key":"10.1016\/j.phrs.2019.104587_bib0030","first-page":"505","article-title":"B-adrenergic blockers in systemic hypertension pharmacokinetic considerations related to the current guidelines","volume":"Vol. 41","author":"Frishman","year":"2002"},{"issue":"November 11","key":"10.1016\/j.phrs.2019.104587_bib0035","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/hr.2014.112","article-title":"Expression and functions of \u03b21- and \u03b22-adrenergic receptors on the bulbospinal neurons in the rostral ventrolateral medulla","volume":"1","author":"Oshima","year":"2014","journal-title":"Hypertens. Res."},{"issue":"February 5","key":"10.1016\/j.phrs.2019.104587_bib0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"2014","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"March 7440","key":"10.1016\/j.phrs.2019.104587_bib0045","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/bmj.328.7440.634","article-title":"British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary","volume":"328","author":"Williams","year":"2004","journal-title":"BMJ"},{"issue":"July 7","key":"10.1016\/j.phrs.2019.104587_bib0050","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"2013","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"issue":"October","key":"10.1016\/j.phrs.2019.104587_bib0055","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ."},{"issue":"February 2","key":"10.1016\/j.phrs.2019.104587_bib0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HJH.0000000000000447","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"issue":"June 12","key":"10.1016\/j.phrs.2019.104587_bib0065","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","article-title":"Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis","volume":"174","author":"Khan","year":"2006","journal-title":"CMAJ."},{"issue":"May 5 Suppl","key":"10.1016\/j.phrs.2019.104587_bib0070","first-page":"S47","article-title":"Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis","volume":"30","author":"Kuyper","year":"2014","journal-title":"Can. J. Cardiol."},{"issue":"November 19","key":"10.1016\/j.phrs.2019.104587_bib0075","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA."},{"issue":"November 5","key":"10.1016\/j.phrs.2019.104587_bib0080","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1053\/j.ajkd.2006.08.004","article-title":"Cardiovascular outcomes in the african american study of kidney disease and hypertension (AASK) trial","volume":"48","author":"Norris","year":"2006","journal-title":"Am. J. Kidney Dis."},{"issue":"September 3","key":"10.1016\/j.phrs.2019.104587_bib0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/01.HYP.26.3.377","article-title":"Isolated diastolic hypertension. A favorable finding among young and middle-aged hypertensive subjects","volume":"26","author":"Fang","year":"1995","journal-title":"Hypertens (Dallas, Tex 1979)"},{"issue":"November 5","key":"10.1016\/j.phrs.2019.104587_bib0090","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/HYPERTENSIONAHA.111.173104","article-title":"Role of elevated heart rate in the development of cardiovascular disease in hypertension","volume":"58","author":"Palatini","year":"2011","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"10.1016\/j.phrs.2019.104587_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/5584_2016_36","article-title":"The role of beta-blockers in the treatment of hypertension","volume":"956","author":"Cruickshank","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"July 6488","key":"10.1016\/j.phrs.2019.104587_bib0100","first-page":"97","article-title":"MRC trial of treatment of mild hypertension: principal results","volume":"291","author":"Medical Research Council Working Party","year":"1985","journal-title":"Br. Med. J. Clin. Res. Ed (Clin Res Ed)"},{"issue":"September 7160","key":"10.1016\/j.phrs.2019.104587_bib0105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ."},{"issue":"October 15","key":"10.1016\/j.phrs.2019.104587_bib0110","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"February 1","key":"10.1016\/j.phrs.2019.104587_bib0115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1567201811310010011","article-title":"Beta3-adrenoreceptors in cardiovasular diseases: new roles for an \u201cold\u201d receptor","volume":"10","author":"Balligand","year":"2013","journal-title":"Curr. Drug Deliv."},{"issue":"September 3","key":"10.1016\/j.phrs.2019.104587_bib0120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/01.RES.53.3.389","article-title":"Mechanism of constriction of large coronary arteries by beta-adrenergic receptor blockade","volume":"53","author":"Vatner","year":"1983","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104587_bib0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00005344-197909000-00001","article-title":"Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol","volume":"1","author":"Lund-Johansen","year":"1979","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"July 1","key":"10.1016\/j.phrs.2019.104587_bib0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/01.HYP.24.1.56","article-title":"Exercise blood pressure predicts cardiovascular mortality in middle-aged men","volume":"24","author":"Mundal","year":"1994","journal-title":"Hypertens (Dallas, Tex 1979)"},{"issue":"February 4","key":"10.1016\/j.phrs.2019.104587_bib0135","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jacc.2005.09.057","article-title":"Beta-blockade mitigates exercise blood pressure in hypertensive male patients","volume":"47","author":"Kokkinos","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"September 18","key":"10.1016\/j.phrs.2019.104587_bib0140","doi-asserted-by":"crossref","first-page":"7042","DOI":"10.1158\/0008-5472.CAN-10-0522","article-title":"The sympathetic nervous system induces a metastatic switch in primary breast cancer","volume":"70","author":"Sloan","year":"2010","journal-title":"Cancer Res."},{"issue":"October","key":"10.1016\/j.phrs.2019.104587_bib0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbi.2016.06.011","article-title":"beta2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer","volume":"57","author":"Chang","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"March 3","key":"10.1016\/j.phrs.2019.104587_bib0150","first-page":"1144","article-title":"The beta2-adrenoceptor activates a positive cAMP-calcium feedforward loop to drive breast cancer cell invasion","volume":"30","author":"Pon","year":"2016","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"issue":"March 5","key":"10.1016\/j.phrs.2019.104587_bib0155","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"July 7\u20138","key":"10.1016\/j.phrs.2019.104587_bib0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18632\/oncoscience.357","article-title":"Beta-adrenergic receptors are expressed across diverse cancers","volume":"4","author":"Rains","year":"2017","journal-title":"Oncoscience."},{"issue":"February 2","key":"10.1016\/j.phrs.2019.104587_bib0165","article-title":"Propranolol for off-label treatment of patients with melanoma: results from a cohort study","volume":"4","author":"De Giorgi","year":"2018","journal-title":"JAMA Oncol."},{"issue":"July 1","key":"10.1016\/j.phrs.2019.104587_bib0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2018.03.024","article-title":"Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies","volume":"121","author":"Yap","year":"2018","journal-title":"Br. J. Anaesth."},{"issue":"February 4","key":"10.1016\/j.phrs.2019.104587_bib0175","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.phrs.2019.104587_bib0180","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: a meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco. Ther."},{"issue":"July 7","key":"10.1016\/j.phrs.2019.104587_bib0185","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00432-014-1658-7","article-title":"Meta-analysis of the effects of beta blocker on survival time in cancer patients","volume":"140","author":"Choi","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"June","key":"10.1016\/j.phrs.2019.104587_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2016.04.004","article-title":"Beta blockers and cancer prognosis - the role of immortal time bias: a systematic review and meta-analysis","volume":"47","author":"Weberpals","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"September 5","key":"10.1016\/j.phrs.2019.104587_bib0195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CEJ.0000000000000192","article-title":"Beta-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies","volume":"25","author":"Zhong","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"issue":"November 11","key":"10.1016\/j.phrs.2019.104587_bib0200","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2013.09.001","article-title":"Effect of beta-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death","volume":"88","author":"De Giorgi","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"October 19","key":"10.1016\/j.phrs.2019.104587_bib0205","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1002\/cncr.29392","article-title":"Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer","volume":"121","author":"Watkins","year":"2015","journal-title":"Cancer."},{"issue":"August 16","key":"10.1016\/j.phrs.2019.104587_bib0210","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-17-0152","article-title":"Perioperative COX-2 and beta-adrenergic blockade improves metastatic biomarkers in breast Cancer patients in a Phase-II randomized trial","volume":"23","author":"Shaashua","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"April 8","key":"10.1016\/j.phrs.2019.104587_bib0215","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.4049\/jimmunol.1501677","article-title":"Propranolol attenuates surgical stress-induced elevation of the regulatory t cell response in patients undergoing radical mastectomy","volume":"196","author":"Zhou","year":"2016","journal-title":"J. Immunol."},{"issue":"July 1","key":"10.1016\/j.phrs.2019.104587_bib0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ijc.30062","article-title":"Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis","volume":"139","author":"Raimondi","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"July 13","key":"10.1016\/j.phrs.2019.104587_bib0225","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","article-title":"Beta-blocker drug use and survival among patients with pancreatic adenocarcinoma","volume":"77","author":"Udumyan","year":"2017","journal-title":"Cancer Res."},{"issue":"November 11","key":"10.1016\/j.phrs.2019.104587_bib0230","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1001\/jamadermatol.2015.2554","article-title":"Growth attenuation of cutaneous angiosarcoma with propranolol-mediated beta-blockade","volume":"151","author":"Chow","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"March 3\u20134","key":"10.1016\/j.phrs.2019.104587_bib0235","doi-asserted-by":"crossref","first-page":"109","DOI":"10.18632\/oncoscience.413","article-title":"Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma","volume":"5","author":"Amaya","year":"2018","journal-title":"Oncoscience."},{"issue":"April","key":"10.1016\/j.phrs.2019.104587_bib0240","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","article-title":"Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study","volume":"6","author":"Pasquier","year":"2016","journal-title":"EBioMedicine."},{"issue":"June 1","key":"10.1016\/j.phrs.2019.104587_bib0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13023-017-0664-7","article-title":"Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease","volume":"12","author":"Albinana","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"June 1","key":"10.1016\/j.phrs.2019.104587_bib0250","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1038\/s41598-017-02913-8","article-title":"Pre- and post-diagnostic beta-blocker use and lung cancer survival: a population-based cohort study","volume":"7","author":"Weberpals","year":"2017","journal-title":"Sci. Rep."},{"issue":"March 3","key":"10.1016\/j.phrs.2019.104587_bib0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/head.12074","article-title":"The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies","volume":"53","author":"Smitherman","year":"2013","journal-title":"Headache."},{"issue":"January 5","key":"10.1016\/j.phrs.2019.104587_bib0260","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology."},{"issue":"September 5","key":"10.1016\/j.phrs.2019.104587_bib0265","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: a population-based case-control study","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology."},{"issue":"August 4 Headache","key":"10.1016\/j.phrs.2019.104587_bib0270","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/CON.0000000000000199","article-title":"Preventive migraine treatment","volume":"21","author":"Silberstein","year":"2015","journal-title":"Continuum (Minneap Minn)."},{"issue":"7","key":"10.1016\/j.phrs.2019.104587_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PLoS One"},{"issue":"April 17","key":"10.1016\/j.phrs.2019.104587_bib0280","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology."},{"issue":"April 2","key":"10.1016\/j.phrs.2019.104587_bib0285","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","article-title":"Current prophylactic medications for migraine and their potential mechanisms of action","volume":"15","author":"Sprenger","year":"2018","journal-title":"Neurotherapeutics."},{"issue":"July 7","key":"10.1016\/j.phrs.2019.104587_bib0290","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jash.2017.05.001","article-title":"Comparative efficacy of \u03b2-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysis","volume":"11","author":"Zhang","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"issue":"April 2","key":"10.1016\/j.phrs.2019.104587_bib0295","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev [Internet]"},{"issue":"March 4","key":"10.1016\/j.phrs.2019.104587_bib0300","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11940-019-0556-3","article-title":"Beta-blockers for migraine prevention: a review article","volume":"21","author":"Danesh","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"September 9","key":"10.1016\/j.phrs.2019.104587_bib0305","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1468-2982.2007.01377.x","article-title":"Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study","volume":"27","author":"Siniatchkin","year":"2007","journal-title":"Cephalalgia."},{"issue":"December 4","key":"10.1016\/j.phrs.2019.104587_bib0310","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1468-2982.1986.0604229.x","article-title":"Contingent negative variation and efficacy of beta-blocking agents in migraine","volume":"6","author":"Schoenen","year":"1986","journal-title":"Cephalalgia."},{"issue":"January 1","key":"10.1016\/j.phrs.2019.104587_bib0315","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1526-4610.2000.00005.x","article-title":"Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials","volume":"40","author":"Sandor","year":"2000","journal-title":"Headache."},{"issue":"April 2","key":"10.1016\/j.phrs.2019.104587_bib0320","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-018-0614-7","article-title":"Targeted nitric oxide synthase inhibitors for migraine","volume":"15","author":"Pradhan","year":"2018","journal-title":"Neurotherapeutics."},{"issue":"April 2","key":"10.1016\/j.phrs.2019.104587_bib0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11916-004-0022-z","article-title":"Prophylactic migraine therapy: mechanisms and evidence","volume":"8","author":"Ramadan","year":"2004","journal-title":"Curr. Pain Headache Rep."},{"issue":"July 1","key":"10.1016\/j.phrs.2019.104587_bib0330","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.0306-5251.2001.01417.x","article-title":"Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B\/1D agonist: differential effects of propranolol, nadolol and metoprolol","volume":"52","author":"Goldberg","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"June 6","key":"10.1016\/j.phrs.2019.104587_bib0335","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","article-title":"The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines","volume":"52","author":"Loder","year":"2012","journal-title":"Headache"},{"issue":"September 9","key":"10.1016\/j.phrs.2019.104587_bib0340","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force","volume":"16","author":"Evers","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"November 5","key":"10.1016\/j.phrs.2019.104587_bib0345","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0404.2008.01087.x","article-title":"A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis","volume":"118","author":"Ashtari","year":"2008","journal-title":"Acta Neurol. Scand."},{"issue":"August 8","key":"10.1016\/j.phrs.2019.104587_bib0350","first-page":"943","article-title":"Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control","volume":"251","author":"Diener","year":"2004","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104587_bib0355","article-title":"Propranolol for migraine prophylaxis","volume":"2017","author":"Linde","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"January 1","key":"10.1016\/j.phrs.2019.104587_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1984.tb07772.x","article-title":"Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial","volume":"69","author":"Tfelt-Hansen","year":"1984","journal-title":"Acta Neurol. Scand."},{"issue":"March 2","key":"10.1016\/j.phrs.2019.104587_bib0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1526-4610.1985.hed2502107.x","article-title":"Clomipramine and metoprolol in migraine prophylaxis--a double-blind crossover study","volume":"25","author":"Langohr","year":"1985","journal-title":"Headache."},{"issue":"December 4","key":"10.1016\/j.phrs.2019.104587_bib0370","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1468-2982.1988.0804279.x","article-title":"Symptoms of classic migraine attacks: modifications brought about by metoprolol","volume":"8","author":"Hedman","year":"1988","journal-title":"Cephalalgia."},{"issue":"February 1","key":"10.1016\/j.phrs.2019.104587_bib0375","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2524.1988.hed2801015.x","article-title":"Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up","volume":"28","author":"Steiner","year":"1988","journal-title":"Headache."},{"issue":"September 3","key":"10.1016\/j.phrs.2019.104587_bib0380","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.0306-5251.2001.01459.x","article-title":"The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers","volume":"52","author":"Limmroth","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"September 8","key":"10.1016\/j.phrs.2019.104587_bib0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1526-4610.1987.hed2708421.x","article-title":"Comparative efficacy of nadolol and propranolol in the management of migraine","volume":"27","author":"Sudilovsky","year":"1987","journal-title":"Headache."},{"issue":"10","key":"10.1016\/j.phrs.2019.104587_bib0390","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-7061(98)00141-1","article-title":"Antihypertensive therapy and insulin sensitivity: do we have to rede\ufb01ne the role of beta blocking agents?","volume":"11","author":"Jacob","year":"1998","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2019.104587_bib0395","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.1997.03550010054039","article-title":"Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas","volume":"278","author":"Shorr","year":"1997","journal-title":"JAMA."},{"key":"10.1016\/j.phrs.2019.104587_bib0400","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2019.104587_bib0405","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"2016","author":"PONIKOWSKI","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.phrs.2019.104587_bib0410","series-title":"Global Strategy for Asthma Management and Prevention","author":"Global Initiative for Asthma","year":"2016"},{"key":"10.1016\/j.phrs.2019.104587_bib0415","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003566","article-title":"Cardioselective beta\u2010blockers for reversible airway disease","volume":"4","author":"SALPETER","year":"2002","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819320936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819320936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:07:15Z","timestamp":1760911635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819320936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":83,"alternative-id":["S1043661819320936"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104587","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-blockers: Their new life from hypertension to cancer and migraine","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104587"}}